"The medical insurance fund is not enough"?The National Medical Insurance Bureau is rumored: balanced revenue and expenditure, slightly balanced

A news that "some medicines will be transferred out of local medical insurance catalogs at the end of the year" aroused social attention.

Some public opinion believes that "the medical insurance fund is not enough", and others believe that the medicines for medical insurance are cheap old medicines. In the future, patients can only choose high -priced medicines.

For these misunderstandings, on July 23, the National Medical Insurance Bureau responded in the form of "answering reporters' question".

The responsible comrades of the Medical Management Department of the National Medical Insurance Bureau introduced: In 2021, the National Basic Medical Insurance Fund (including maternity insurance) revenue was 2.88 trillion yuan, and expenditure was 2.4 trillion yuan. In general, the revenue and expenditure of the National Medical Insurance Fund is slightly balanced, and the fund guarantee capabilities are stable and sustainable.

The National Medical Insurance Bureau did not make it clear that in 2021, the medical insurance fund was still greater than the support in the context of undertaking a large number of new crown vaccine vaccination expenditures. In other words, the medical insurance fund is fully capable of affording the daily medical needs of the people.

As for the addition of varieties to clean up the medical insurance catalog, it has other profound meaning.

Last year's medical conclusion was 40 million remaining

The scope of basic medical insurance drugs in the country is basically unified. This is the required requirements in the "Fourteenth Five -Year Plan" National Medical Security Plan.

At the beginning of the establishment of the medical insurance system, there were few national medical insurance varieties, and there were large differences in drug habits between regions. The state allowed all localities to allow some varieties to be supplemented by themselves according to its own economic level, but it could not exceed 15%of the number of "category B drugs" of the national directory. The right to use the right to use public medicine.

Over time, there are many high -priced and uncertain "universal drugs" in the local supplementary catalog.

Analysts pointed out: "In the past, the products of pharmaceutical companies could be easily achieved by products that entered the provincial medical insurance directory." Some pharmaceutical companies even deliberately did not apply for national medical insurance, but seemed to be qualified in various provinces in order to use the information of various provinces to use the information of various provinces Poor, sell high prices in some areas to get excess returns.

The adding directory of the medical insurance place is the last umbrella of these varieties. The country has clearly eliminated these clinical efficacy and the low -faire price -ratio products. It is logical.

On the other hand, the national medical insurance capabilities and levels have improved rapidly, and the provinces have become no longer necessary. Officials of the State Medical Insurance Bureau emphasized in the "Answers": Now the national medical insurance directory dynamic adjustment every year. Since the four years since 2018, 507 drugs have been included in the medical insurance directory through negotiations, and the variety prices have been greatly reduced.

In fact, the National Medical Insurance Bureau has been continuously cleaning up the varieties of inaccurate effects in the national medical insurance varieties, and has cleaned 391 medicines for 4 years.

Therefore, it is logical to replenish the place of reign.

As early as August 2019, the National Medical Insurance Administration determined that from 2020, the proportion of provincial -level supplements was gradually transferred to the provincial -level supplementary varieties at a ratio of 40%, 2nd year, and 20%in the third year. Medical insurance drugs are unified.

As of June 30 this year, 15 provinces and Xinjiang Production and Construction Corps have completed the clearance of all local supplements in advance. The remaining 16 provinces such as Beijing will be completed by the end of this year.

Analysts pointed out that the basis of the scope of medical insurance drugs is basically unified, which is an important measure to solve the problem of inadequate problems in the field of medical security in China. Medical security services.

Misunderstanding of the media

地方医保增补品种清退，其实已经进行了3年，这次突然会被关注到，是因为部分媒体在转发北京市第三批“消化”医保药品时候的消息时，突出“调出药品含氨"Chlorine, ibuprofen, etc." content.

The National Medical Insurance Bureau believes that some media "have some misunderstandings."

Ammonia is a commonly used hypertension. The mainstream dosage is tablets or capsules. Dozens of domestic companies are produced. From September 2021 to June 2022, the Beijing Medical Insurance Fund actually paid nearly 300 million yuan in various dosage types.

The Beijing Medical Insurance Catalog is called "Ammlid Drop Pills".

The dosage type was once a pseudo -innovation routine of domestic pharmaceutical companies. More than ten years ago, domestic companies could only do imitation medicines, and the price was limited. If you want to break through the price limit and you can't do innovative medicines, you can only find a way in the dosage form. If you change the dosage form, you can enjoy the policy of separate pricing.

These varieties have long -term existence on the local supplementary catalog, so that many companies have made a lot of money. All this time is cleared and deserved.

According to statistics from the Beijing Medical Insurance Department: In the past nine months, the hospital in Beijing has hardly used this medicine clinically, and the amount of medical insurance reimbursement is 0.

Another category of retreat is the Chinese medicine and auxiliary medication. For example, thymptide injections, millet injection, Pudi blue oral solution and other varieties of the hospital market. After the regression of various places, the performance of the relevant production enterprises such as Bobby Pharmaceutical and Jichuan Pharmaceuticals was "changed", which was affected in the short term.

The pain is always inevitable. After canceling the local supplement, this is more conducive to the National Medical Insurance Bureau to grasp the "money bag" and use the "life -saving money" to the maximum to the blade.

In response, the National Medical Insurance Bureau particularly mentioned this year's medical insurance price negotiations: the review process will be jointly reviewed by the comprehensive group and professional group experts, and non -independent varieties will be allowed to enter the negotiations, and the medical insurance payment standards are determined by bidding. Encourage rare medical medication, child medication application, etc.

These measures all show that while the National Medical Insurance Bureau adds the category of supplementing the catalog, it is also actively absorbing new drugs and good medicines to join medical insurance to ensure the needs of people's medication.#National Medical Insurance Bureau ## ###

- END -